Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination With the CDK4/6 Inhibitor Ribociclib, With the PI3K Inhibitor Alpelisib, With the mTOR Inhibitor Everolimus, or With CDK4 Inhibitor Atirmociclib in Adult Subjects With Advanced and/or Metastatic ER Positive, HER2 Negative Breast Cancer

NCT05508906 is registered in ClinicalTrials.gov with Olema Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05508906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05508906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination With the CDK4/6 Inhibitor Ribociclib, With the PI3K Inhibitor Alpelisib, With the mTOR Inhibitor Everolimus, or With CDK4 Inhibitor Atirmociclib in Adult Subjects With Advanced and/or Metastatic ER Positive, HER2 Negative Breast Cancer
Lead sponsor
Olema Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 31, 2022
Completion date
January 31, 2028
Enrollment
190 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, er-positive breast cancer, her2-negative breast cancer, locally advanced breast cancer, metastatic breast cancer